Labaran Kamfani

Wani bincike mai zurfi ya nuna tasirin maganin ƙwayoyin CAR-T wajen magance cutar sankarar jini ta B-cell mai tsanani (B-ALL). Binciken, wanda ya haɗa da haɗin gwiwa da BIOOCUS da Asibitin Lu Daopei, ya nuna ci gaba mai mahimmanci, yana mai tabbatar da maganin a matsayin wani zaɓi mai mahimmanci na magani.

Masu bincike daga Asibitin Lu Daopei da abokan hulɗa na ƙasashen duniya suna bincike kan hanyoyin magance ƙwayoyin CAR-T na zamani, suna ba da bege ga marasa lafiya da ke fama da cutar B cells. Wannan binciken ya nuna ci gaba a cikin ƙira da amfani, yana nuna sakamako mai kyau da kuma yuwuwar sabbin abubuwa a nan gaba.

Binciken asibiti na baya-bayan nan ya nuna cewa ƙwayoyin CAR-T masu tushen CD19 4-1BB suna nuna ingantaccen ingancin maganin ƙari idan aka kwatanta da ƙwayoyin CAR-T masu tushen CD28 wajen magance cutar sankarar lymphoblastic mai saurin kamuwa da cutar B cell (r/r B-ALL).

Wani bincike da aka yi kwanan nan a Asibitin Lu Daopei ya nuna inganci da amincin maganin ƙwayoyin CAR-T na CD19 mai ƙarancin allurai wajen magance marasa lafiya da suka kamu da cutar B-Acute lymphoblastic leukemia (B-ALL). Binciken, wanda ya haɗa da marasa lafiya 51, ya nuna cikakken saurin warkewa tare da ƙarancin illa.

Asibitin Lu Daopei da Hebei Senlang Biotechnology sun sanar da sakamako mai kyau daga binciken da suka yi kwanan nan kan aminci da ingancin maganin CAR-T ga cutar sankarar jini ta ƙwayoyin B mai tsanani. Wannan haɗin gwiwar ya nuna yuwuwar sabbin ƙirar ƙwayoyin CAR-T don haɓaka sakamakon marasa lafiya.

Wani sabon bincike da Dr. Zhi-tao Ying daga Asibitin Cutar Daji na Jami'ar Peking ya jagoranta ya nuna aminci da ingancin maganin ƙwayoyin cuta na IM19 CAR-T wajen magance cututtukan jini na ƙwayoyin B da suka sake dawowa da kuma waɗanda ba sa iya jurewa. An buga a cikin Mujallar Sin game da Sabbin Magunguna, binciken ya ba da rahoton cewa marasa lafiya 11 cikin 12 sun sami cikakkiyar sassauci ba tare da wata mummunar illa ba, wanda ke nuna yuwuwar IM19 a matsayin zaɓi mai kyau na magani ga marasa lafiya waɗanda ke da ƙarancin zaɓuɓɓuka.

An gudanar da horon shekara-shekara na 2024 don kula da jini da fasahar zubar jini a Asibitin Yanda Ludaopei cikin nasara. Wannan taron yana da nufin inganta kula da jini da kuma kare shi daga zubar jini ta hanyar cikakken zaman horo wanda kwararrun kiwon lafiya sama da 100 daga cibiyoyin kiwon lafiya daban-daban suka halarta.

Tabbatar da samun ingantaccen magani ga masu fama da cutar sankarar jini ya ƙunshi kulawa ta yau da kullun, gami da tsaftace muhalli, tsaftace jiki, abinci mai gina jiki, da kuma motsa jiki mai kyau. Wannan jagorar tana ba da shawarwari masu mahimmanci don ingantaccen kulawa ta yau da kullun don tallafawa murmurewa.

Wani bincike da aka yi kwanan nan ya nuna inganci da amincin maganin ƙwayoyin NS7CAR-T wajen magance cutar sankarar jini mai saurin kamuwa da cutar T-cell lymphoblastic leukemia (R/R T-ALL) da kuma cutar sankarar lymphoblastic ta T-cell (R/R T-LBL). Wannan maganin yana ba da sabon bege ga marasa lafiya da ke fama da waɗannan nau'ikan cutar kansa masu tsanani.

An shirya gudanar da taron shekara-shekara na Lu Daopei Hematology Forum na 12 a ranakun 23-24 ga Agusta, 2024, a Cibiyar Taro ta Duniya ta Beijing. Ku kasance tare da mu don tattaunawa mai zurfi da kuma sabbin ci gaba a fannin ilimin jini.

Wani bincike na asibiti na mataki na I na CD7 CAR-T don R/R AML daga ƙungiyar Daopei Lu ya fara a ASH. An gudanar da taron shekara-shekara na 65 na Ƙungiyar Nazarin Hematology ta Amurka (ASH) ba tare da intanet ba (San Diego, Amurka) kuma a yanar gizo a ranar 9-12 ga Disamba, 2023. Masananmu sun nuna wannan gagarumin...

Ƙungiyar Nazarin Jini ta Amurka (ASH) ita ce babbar taron ilimi a fannin ilimin jinin jini a duk duniya. Gaskiyar cewa an zaɓi Asibitin Lu Daopei a matsayin wanda ya yi nasara a ASH tsawon shekaru a jere ya nuna nasarorin da ya samu a fannin ilimi a...